These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35290656)

  • 1. Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective.
    Labouta HI; Langer R; Cullis PR; Merkel OM; Prausnitz MR; Gomaa Y; Nogueira SS; Kumeria T
    Drug Deliv Transl Res; 2022 Nov; 12(11):2581-2588. PubMed ID: 35290656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
    Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
    Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.
    Granados-Riveron JT; Aquino-Jarquin G
    Biomed Pharmacother; 2021 Oct; 142():111953. PubMed ID: 34343897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Learning lessons from lipids to make COVID-19 vaccines.
    Cell; 2022 Apr; 185(8):1279-1282. PubMed ID: 35385689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Materials for SARS-CoV-2 Vaccines.
    Mabrouk MT; Huang WC; Martinez-Sobrido L; Lovell JF
    Adv Mater; 2022 Mar; 34(12):e2107781. PubMed ID: 34894000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of lipid constituents in lipid nanoparticle mRNA delivery systems.
    Wu S; Lin L; Shi L; Liu S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(4):e1978. PubMed ID: 38965928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab.
    Jarzebska NT; Frei J; Mellett M; Kündig TM; Pascolo S; Reichmuth AM
    Methods Mol Biol; 2024; 2786():237-254. PubMed ID: 38814398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic.
    Tsakiri M; Naziris N; Demetzos C
    Int J Pharm; 2021 Dec; 610():121212. PubMed ID: 34687816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited].
    Jawalagatti V; Kirthika P; Lee JH
    Front Immunol; 2022; 13():884862. PubMed ID: 35592330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.
    Szebeni J; Storm G; Ljubimova JY; Castells M; Phillips EJ; Turjeman K; Barenholz Y; Crommelin DJA; Dobrovolskaia MA
    Nat Nanotechnol; 2022 Apr; 17(4):337-346. PubMed ID: 35393599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines.
    Shepherd SJ; Han X; Mukalel AJ; El-Mayta R; Thatte AS; Wu J; Padilla MS; Alameh MG; Srikumar N; Lee D; Weissman D; Issadore D; Mitchell MJ
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303567120. PubMed ID: 37556502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles for designing an optimal mRNA lipid nanoparticle vaccine.
    Kon E; Elia U; Peer D
    Curr Opin Biotechnol; 2022 Feb; 73():329-336. PubMed ID: 34715546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
    Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
    J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
    Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
    ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery
    Hadjiargyrou M
    Nucleic Acid Ther; 2021 Oct; 31(5):321-323. PubMed ID: 33960839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
    Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
    Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery.
    van Rijn CJM; Vlaming KE; Bem RA; Dekker RJ; Poortinga A; Breit T; van Leeuwen S; Ensink WA; van Wijnbergen K; van Hamme JL; Bonn D; Geijtenbeek TBH
    Sci Rep; 2023 May; 13(1):8851. PubMed ID: 37258559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.